Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: a feasibility study.
Elaine M WalshAyca GucalpSujata PatilMarcia EdelweissDara S RossPedram RazaviShanu ModiNeil M IyengarRachel SanfordTiffany Troso-SandovalMila GorskyJacqueline BrombergPamela DrullinskyDiana LakeSerena WongPatricia Ann DeFuscoNicholas LamparellaRanja GuptaTasmila TabassumLeigh Ann BoyleArtavazd ArumovTiffany A TrainaPublished in: Breast cancer research and treatment (2022)
This clinical trial demonstrates that adjuvant enzalutamide is a feasible and well-tolerated regimen in patients with an early-stage AR + TNBC. Randomized trials in the metastatic setting may inform patient selection through biomarker development; longer follow-up is needed to determine the effect of anti-androgens on DFS and OS in this patient population.